AstraZeneca Advances Primary Care Lung Diagnosis Study With Global Reach

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study.

The study “A Study to Evaluate the Accuracy of Primary Care Diagnosis Using Oscillometry and Fractional Exhaled Nitric Oxide for Asthma and COPD Versus Specialist Diagnosis in Patients With Suspected Asthma or COPD” tests whether simpler lung tests can help family doctors match specialist diagnoses. It matters because faster, accurate diagnosis may shift care from hospitals to primary care.

The study does not test a new drug but two diagnostic tools. These are oscillometry and FeNO tests, which aim to spot asthma and COPD earlier and more reliably in everyday clinics.

The design is observational and prospective, meaning doctors follow patients forward in time and compare primary care findings with specialist results. There is no randomization or blinding, so the focus is on real world accuracy and practical use rather than cause and effect.

The trial runs in six countries across the Middle East, Asia, and Latin America, using two hospital sites per country to mirror diverse health systems. Primary care doctors receive training based on GINA and GOLD standards, then assess patients once, with specialist review within three days.

The study was first submitted on 6 Oct 2025, marking the formal start of regulatory tracking and site set up. The latest update on 16 Mar 2026 signals that AstraZeneca is actively refining the protocol and that recruitment and operational plans are moving ahead.

Primary completion and overall completion dates are not listed yet, which suggests timelines may span several years as sites ramp up and data mature. Investors should expect meaningful readouts only after recruitment and central analyses are complete, likely beyond the near term.

For AstraZeneca, this program supports its long term respiratory strategy by strengthening its role in diagnosis and disease management, not just drug sales. Better primary care tools could also increase the diagnosed patient pool for existing asthma and COPD drugs such as Symbicort and newer inhaled treatments.

The update may offer a modest positive signal for AZN by reinforcing its focus on emerging markets and integrated care pathways. It also positions the company well against peers like GSK and Novartis in a crowded respiratory field where accurate diagnosis underpins market share.

Because this study is not tied to a single high margin product, near term earnings impact is limited, but it supports AstraZeneca’s brand with payers and health systems. Over time, proof that simple tests improve diagnosis could support broader guideline uptake, increasing volume across the company’s respiratory portfolio.

Overall, the ongoing study highlights AstraZeneca’s push into service based and diagnostic enabled models that can deepen customer ties in primary care. The trial remains active and updated, with further operational and scientific details available on the ClinicalTrials portal.

To learn more about GB:AZN’s potential, visit the AstraZeneca plc drug pipeline page.